VLUE vs XBI
iShares MSCI USA Value Factor ETF vs SPDR S&P Biotech ETF
- • VLUE has the lower expense ratio at 0.15% vs 0.35% for XBI.
- • VLUE pays a higher dividend yield (1.70%).
Side-by-side metrics
| Metric | VLUE | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.15% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.70% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $12.05B | $8.30B |
YTD return | 30.27% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.12 | 1.09 |
P/E ratio | 19.08 | — |
Last price | $174.81 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
VLUE top holdings
| MU | Micron Technology Inc | 11.62% |
| INTC | Intel Corp | 9.28% |
| CSCO | Cisco Systems Inc | 4.90% |
| AMAT | Applied Materials Inc | 3.67% |
| GM | General Motors Co | 3.15% |
| VZ | Verizon Communications Inc | 2.66% |
| T | AT&T Inc | 2.53% |
| C | Citigroup Inc | 1.94% |
| WDC | Western Digital Corp | 1.89% |
| BAC | Bank of America Corp | 1.88% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VLUE
VLUE (iShares MSCI USA Value Factor ETF) is US stocks with attractive valuations vs fundamentals. Managed by iShares, the fund carries $12.0B in assets under management, an expense ratio of 0.15%, a dividend yield of 1.70%. Its largest holding is Micron Technology Inc (MU), which represents 11.6% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.